ERBB2 and breast carcinoma: The SWOG S8814 analysis showed that patients with RS <18 did not benefit from chemotherapy, in an analysis that was prespecified and therefore designed to address the question of chemotherapy benefit.18 Similarly, an NSABP B-20 analysis demonstrated that RS results can predict chemotherapy benefit in patients with node-negative, ER+ breast cancer.19 As such, the 21-gene test is the only genomic assay with level 1 evidence of chemotherapy benefit prediction in HR+, HER2-negative breast cancer in both the N+ and node-negative settings.18,19